Top

Published in:

01-04-2012 | Preclinical study

KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

Authors: Muralidharan Anbalagan, Latonya Carrier, Seth Glodowski, David Hangauer, Bin Shan, Brian G. Rowan

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Abstract

KX-01 is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase. The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα positive breast cancer in vitro and in vivo. Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase. Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis. KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint. Apoptosis resulted from activation of caspases 6, 7, 8, and 9. Combinational index analysis revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines. KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were associated with reduced ERα transcriptional activity. Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition. Immunohistochemical analysis revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition. Combinations of KX-01 with endocrine therapy present a promising new strategy for clinical management of ERα positive breast cancer.

Available only for authorised users

Sakorafas GH, Farley DR, Peros G (2008) Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev 34(6):483–497. doi:10.1016/j.ctrv.2008.03.001 PubMedCrossRef

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 90(18):1371–1388PubMedCrossRef

Swerdlow AJ, Jones ME (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97(5):375–384. doi:10.1093/jnci/dji057 PubMedCrossRef

Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B (2007) Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 25(27):4201–4209. doi:10.1200/JCO.2006.09.4318 PubMedCrossRef

Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-src interactions in breast cancer. Breast Cancer Res 2(3):203–210PubMedCrossRef

Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, Bohmer FD (2001) Elevated activity and expression of src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 127(4):226–230PubMedCrossRef

Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG, Edwards J (2009) Is expression or activation of src kinase associated with cancer-specific survival in er-, pr- and her2-negative breast cancer patients? Am J Pathol 175(4):1389–1397. doi:10.2353/ajpath.2009.090273 PubMedCrossRef

Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM (2008) Signal transducer and activator of transcription 5b, c-src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 22(8):1781–1796. doi:10.1210/me.2007-0419 PubMedCrossRef

Hiscox S, Morgan L, Green T, Nicholson RI (2006) Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 13 Suppl 1:S53–S59. doi:10.1677/erc.1.01297 PubMedCrossRef

10.

Desouki MM, Rowan BG (2004) Src kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium. Clin Cancer Res 10(2):546–555PubMedCrossRef

11.

Shah YM, Rowan BG (2005) The src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19(3):732–748. doi:10.1210/me.2004-0298 PubMedCrossRef

12.

Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T (2005) Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol 23(13):2980–2987. doi:10.1200/JCO.2005.06.064 PubMedCrossRef

13.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R (2008) Ski-606 (bosutinib), a novel src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185–1194. doi:10.1158/1535-7163.MCT-08-0126 PubMedCrossRef

14.

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on src kinase for survival. Cancer Res 67(6):2800–2808. doi:10.1158/0008-5472.CAN-06-3469 PubMedCrossRef

15.

Kim H, Laing M, Muller W (2005) c-Src-null mice exhibit defects in normal mammary gland development and ERalpha signaling. Oncogene 24(36):5629–5636. doi:10.1038/sj.onc.1208718 PubMedCrossRef

16.

Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ (2001) Potentiation of estrogen receptor activation function 1 (af-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol 15(1):32–45PubMedCrossRef

17.

Jr DH (2007) Kxo1: compositions for treating cell proliferation disorders. 7300931 B2, 27

18.

Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Ple PA, Warin N, Costello G (2006) N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2 h-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49(22):6465–6488. doi:10.1021/jm060434q PubMedCrossRef

19.

Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, Rowan BG (2009) Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118(1):33–43. doi:10.1007/s10549-008-0216-x PubMedCrossRef

20.

Chou TC (1991) Synergism and antagonism in chemotherapy. The median-effect principle and the combination index for quantitation of synergism and antagonism. Academic Press, San Diego

21.

Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM (2009) Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 15(10):3396–3405. doi:10.1158/1078-0432.CCR-08-3127 PubMedCrossRef

22.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319–326. doi:10.1007/s10549-006-9463-x PubMedCrossRef

23.

Doree M, Hunt T (2002) From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 115(Pt 12):2461–2464PubMed

24.

Berry LD, Gould KL (1996) Regulation of Cdc2 activity by phosphorylation at T14/Y15. Prog Cell Cycle Res 2:99–105PubMedCrossRef

25.

Ramalingam S, Natarajan G, Schafer C, Subramaniam D, May R, Ramachandran I, Queimado L, Houchen CW, Anant S (2008) Novel intestinal splice variants of rna-binding protein CUGBP2: isoform-specific effects on mitotic catastrophe. Am J Physiol Gastrointest Liver Physiol 294(4):G971–G981. doi:10.1152/ajpgi.00540.2007 PubMedCrossRef

26.

Bonnet J, Mayonove P, Morris MC (2008) Differential phosphorylation of Cdc25c phosphatase in mitosis. Biochem Biophys Res Commun 370(3):483–488. doi:10.1016/j.bbrc.2008.03.117 PubMedCrossRef

27.

Kuang J, Ashorn CL, Gonzalez-Kuyvenhoven M, Penkala JE (1994) Cdc25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor. Mol Biol Cell 5(2):135–145PubMed

28.

Castedo M, Perfettini JL, Roumier T, Kroemer G (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9(12):1287–1293. doi:10.1038/sj.cdd.4401130 PubMedCrossRef

29.

Pascreau G, Arlot-Bonnemains Y, Prigent C (2003) Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res 5:369–374PubMed

30.

Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4(5):303–313. doi:10.1054/drup.2001.0213 PubMedCrossRef

31.

Adjei AA CR, Kurzrock R, Gordon GS, Hangauer D, et al. (2009) Results of a phase i trial of KX2-391, a novel non-atp competitive substrate-pocket directed src inhibitor, in patients with advanced malignancies. J Clin Oncol 27 (suppl; abstr 3511):1

32.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI (2009) Dual targeting of src and er prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 115(1):57–67. doi:10.1007/s10549-008-0058-6 PubMedCrossRef

33.

Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S (2009) Elevated src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 8(16):1550–1558PubMedCrossRef

34.

Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J (2007) P27 phosphorylation by src regulates inhibition of cyclin e-cdk2. Cell 128(2):281–294. doi:10.1016/j.cell.2006.11.049 PubMedCrossRef

35.

Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA (2006) Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5(12):3023–3031. doi:10.1158/1535-7163.MCT-06-0394 PubMedCrossRef

36.

Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI (2002) Estrogen action via the g protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16(1):70–84PubMedCrossRef

37.

Song RX, Zhang Z, Santen RJ (2005) Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab 16(8):347–353. doi:10.1016/j.tem.2005.06.010 PubMedCrossRef

38.

Weigel NL, Moore NL (2007) Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 21(10):2311–2319. doi:10.1210/me.2007-0101 PubMedCrossRef

39.

Castano E, Vorojeikina DP, Notides AC (1997) Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochem J 326(Pt 1):149–157PubMed

40.

Arnold SF, Obourn JD, Jaffe H, Notides AC (1995) Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase ii: consequence on DNA binding. J Steroid Biochem Mol Biol 55(2):163–172PubMedCrossRef

41.

Roche S, Fumagalli S, Courtneidge SA (1995) Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science 269(5230):1567–1569PubMedCrossRef

42.

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N (1999) Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 59(24):6145–6152PubMed

43.

Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martin-Perez J (2006) Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 281(30):20851–20864. doi:10.1074/jbc.M601570200 PubMedCrossRef

44.

Kasahara K, Nakayama Y, Nakazato Y, Ikeda K, Kuga T, Yamaguchi N (2007) Src signaling regulates completion of abscission in cytokinesis through ERK/MAPK activation at the midbody. J Biol Chem 282(8):5327–5339. doi:10.1074/jbc.M608396200 PubMedCrossRef

45.

Garcia-Martinez JM, Calcabrini A, Gonzalez L, Martin-Forero E, Agullo-Ortuno MT, Simon V, Watkin H, Anderson SM, Roche S, Martin-Perez J (2010) A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal 22(3):415–426. doi:10.1016/j.cellsig.2009.10.013 PubMedCrossRef

46.

Finlay D, Vuori K (2007) Novel noncatalytic role for caspase-8 in promoting Src-mediated adhesion and erk signaling in neuroblastoma cells. Cancer Res 67(24):11704–11711. doi:10.1158/0008-5472.CAN-07-1906 PubMedCrossRef

47.

Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X (2008) Tamoxifen and trail synergistically induce apoptosis in breast cancer cells. Oncogene 27(10):1472–1477. doi:10.1038/sj.onc.1210749 PubMedCrossRef

48.

Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA (1999) Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17(9):2633–2638PubMed

49.

Park SI, Shah AN, Zhang J, Gallick GE (2007) Regulation of angiogenesis and vascular permeability by src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 11(9):1207–1217. doi:10.1517/14728222.11.9.1207 PubMedCrossRef

50.

Garvin S, Nilsson UW, Dabrosin C (2005) Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 93(9):1005–1010. doi:10.1038/sj.bjc.6602824 PubMedCrossRef

Title: KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer
Authors: Muralidharan Anbalagan
Latonya Carrier
Seth Glodowski
David Hangauer
Bin Shan
Brian G. Rowan
Publication date: 01-04-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1513-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole

Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes

A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity

Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin

Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer

Absence of ectopic epithelial inclusions in 3,904 axillary lymph nodes examined in sentinel technique

Keynote webinar | Spotlight on antibody–drug conjugates in cancer